Ranked after the close on October 30, 2026
Biotechnology stocks
Biotechnology ranks #25 of 140 industry groups, one of the market's strongest groups, with a median 6-month return of +13% across its 149 US stocks above $1B (sector: Healthcare). 6 of them are in today's top 50 leaders.
#25group rank of 140
+13%median, 6 months
149stocks above $1B
6in the top 50
Biotechnology stocks ranked
| # | Stock | Market cap | Off high | Comp | EPS | RS |
|---|---|---|---|---|---|---|
| 1 | HALO Top 50Halozyme Therapeutics, Inc. | $14.9B | 2.3% | |||
| 2 | EXEL Top 50Exelixis, Inc. | $16.9B | 3.8% | |||
| 3 | NRIX Top 50Nurix Therapeutics, Inc. | $2.9B | 5.1% | |||
| 4 | LGND Top 50Ligand Pharmaceuticals Incorpor | $6.5B | 1.2% | |||
| 5 | PTGX Top 50Protagonist Therapeutics, Inc. | $9.4B | 9.9% | |||
| 6 | ONC Top 50BeOne Medicines Ltd. | $42.1B | 4.7% | |||
| 7 | OMEROmeros Corporation | $1.3B | 13.2% | |||
| 8 | RPRXRoyalty Pharma plc | $38.8B | 0.8% | |||
| 9 | ARQTArcutis Biotherapeutics, Inc. | $4.0B | 3.7% | |||
| 10 | CAICaris Life Sciences, Inc. | $9.7B | 5.9% | |||
| 11 | ASNDAscendis Pharma A/S | $16.5B | 10.9% | |||
| 12 | TGTXTG Therapeutics, Inc. | $9.4B | 0.9% | |||
| 13 | AUPHAurinia Pharmaceuticals Inc | $2.2B | 13.5% | |||
| 14 | LKFTLakefront Biotherapeutics | $2.1B | 10.9% | |||
| 15 | SLNSilence Therapeutics Plc - Amer | $1.2B | 0.6% | |||
| 16 | KRYSKrystal Biotech, Inc. | $9.8B | 13.1% | |||
| 17 | VSTMVerastem, Inc. | $1.2B | 9.9% | |||
| 18 | VRTXVertex Pharmaceuticals Incorpor | $141.6B | 0.9% | |||
| 19 | HRMYHarmony Biosciences Holdings, I | $2.3B | 10.9% | |||
| 20 | REPLReplimune Group, Inc. | $1.7B | 3.6% | |||
| 21 | GMABGenmab A/S | $35.1B | 4.9% | |||
| 22 | ARGXargenx SE | $56.1B | 16.8% | |||
| 23 | IOVAIovance Biotherapeutics, Inc. | $3.8B | 44.8% | |||
| 24 | REGNRegeneron Pharmaceuticals, Inc. | $96.0B | 0.8% | |||
| 25 | SYRESpyre Therapeutics, Inc. | $9.0B | 12.4% | |||
| 26 | VIRVir Biotechnology, Inc. | $1.9B | 7.3% | |||
| 27 | TECHBio-Techne Corp | $11.4B | 0.1% | |||
| 28 | SEPNSepterna, Inc. | $2.1B | 13.9% | |||
| 29 | VCELVericel Corporation | $2.1B | 18.4% | |||
| 30 | KODKodiak Sciences Inc | $6.2B | 4.6% | |||
| 31 | PGENPrecigen, Inc. | $2.5B | 22.7% | |||
| 32 | ABSIAbsci Corporation | $1.9B | 11.3% | |||
| 33 | XNCRXencor, Inc. | $2.2B | 11.2% | |||
| 34 | ADMAADMA Biologics Inc | $2.6B | 44.2% | |||
| 35 | JAZZJazz Pharmaceuticals plc | $14.0B | 18.9% | |||
| 36 | BHVNBiohaven Ltd. | $2.3B | 15.5% | |||
| 37 | SLSSELLAS Life Sciences Group, Inc | $2.0B | 39.0% | |||
| 38 | FTREFortrea Holdings Inc. | $2.1B | 18.6% | |||
| 39 | ROIVRoivant Sciences Ltd. | $26.7B | 13.2% | |||
| 40 | MRVIMaravai LifeSciences Holdings, | $2.9B | 17.1% | |||
| 41 | URGNUroGen Pharma Ltd. | $1.6B | 35.6% | |||
| 42 | TARSTarsus Pharmaceuticals, Inc. | $3.5B | 18.2% | |||
| 43 | MRNAModerna, Inc. | $88.5B | 12.9% | |||
| 44 | KYMRKymera Therapeutics, Inc. | $10.8B | 2.6% | |||
| 45 | IBRXImmunityBio, Inc. | $8.8B | 33.3% | |||
| 46 | MANEVeradermics, Incorporated | $5.8B | 4.7% | |||
| 47 | DMRADamora Therapeutics, Inc. | $1.3B | 43.9% | |||
| 48 | TLXTelix Pharmaceuticals Limited | $3.1B | 30.6% | |||
| 49 | SGPSpyGlass Pharma, Inc. | $1.1B | 4.7% | |||
| 50 | TRAXFirst Tracks Biotherapeutics, I | $1.9B | 9.7% | |||
| 51 | VRDNViridian Therapeutics, Inc. | $2.8B | 28.1% | |||
| 52 | LEGNLegend Biotech Corporation | $4.2B | 42.3% | |||
| 53 | ABCLAbCellera Biologics Inc. | $4.0B | 18.3% | |||
| 54 | RLAYRelay Therapeutics, Inc. | $4.0B | 13.7% | |||
| 55 | RXRXRecursion Pharmaceuticals, Inc. | $2.4B | 30.0% | |||
| 56 | ALNYAlnylam Pharmaceuticals, Inc. | $22.1B | 65.6% | |||
| 57 | TWSTTwist Bioscience Corporation | $10.1B | 30.5% | |||
| 58 | NVAXNovavax, Inc. | $1.7B | 24.7% | |||
| 59 | JANXJanux Therapeutics, Inc. | $1.1B | 50.6% | |||
| 60 | RVMDRevolution Medicines, Inc. | $41.0B | 14.7% | |||
| 61 | MESOMesoblast Limited | $2.0B | 29.5% | |||
| 62 | ORKAOruka Therapeutics, Inc. | $6.4B | 16.1% | |||
| 63 | CGONCG Oncology, Inc. | $5.7B | 20.1% | |||
| 64 | INVAInnoviva, Inc. | $1.5B | 15.6% | |||
| 65 | CRSPCRISPR Therapeutics AG | $5.0B | 22.1% | |||
| 66 | PTCTPTC Therapeutics, Inc. | $5.0B | 34.0% | |||
| 67 | ACADACADIA Pharmaceuticals Inc. | $3.5B | 33.5% | |||
| 68 | INCYIncyte Corporation | $24.5B | 9.2% | |||
| 69 | LBRXLB Pharmaceuticals Inc | $1.3B | 20.9% | |||
| 70 | CORTCorcept Therapeutics Incorporat | $8.8B | 35.8% | |||
| 71 | BBIOBridgeBio Pharma, Inc. | $14.6B | 19.8% | |||
| 72 | ERASErasca, Inc. | $5.0B | 40.9% | |||
| 73 | VORVor Biopharma Inc. | $1.2B | 26.5% | |||
| 74 | NBTXNanobiotix S.A. | $1.6B | 45.1% | |||
| 75 | NTLAIntellia Therapeutics, Inc. | $1.7B | 32.5% | |||
| 76 | PVLAPalvella Therapeutics, Inc. | $2.1B | 9.4% | |||
| 77 | ZLABZai Lab Limited | $2.7B | 19.7% | |||
| 78 | IRONDisc Medicine, Inc. | $3.6B | 18.8% | |||
| 79 | IMCRImmunocore Holdings plc | $1.6B | 25.1% | |||
| 80 | ZYMEZymeworks Inc. | $2.1B | 8.7% | |||
| 81 | SMMTSummit Therapeutics Inc. | $12.8B | 45.2% | |||
| 82 | DRTSAlpha Tau Medical Ltd. | $1.2B | 17.3% | |||
| 83 | TNGXTango Therapeutics, Inc. | $3.8B | 33.9% | |||
| 84 | ANABAnaptysBio, Inc. | $1.4B | 33.3% | |||
| 85 | PRAXPraxis Precision Medicines, Inc | $8.0B | 27.2% | |||
| 86 | MBXMBX Biosciences, Inc. | $2.7B | 23.1% | |||
| 87 | EWTXEdgewise Therapeutics, Inc. | $4.2B | 19.8% | |||
| 88 | PHVSPharvaris N.V. | $2.4B | 22.5% | |||
| 89 | PBLSParabilis Medicines, Inc. | $3.5B | 33.3% | |||
| 90 | COGTCogent Biosciences, Inc. | $5.4B | 29.1% | |||
| 91 | TVTXTravere Therapeutics, Inc. | $4.7B | 26.7% | |||
| 92 | BMRNBioMarin Pharmaceutical Inc. | $11.3B | 17.6% | |||
| 93 | DFTXDefinium Therapeutics, Inc. | $4.9B | 26.9% | |||
| 94 | BEAMBeam Therapeutics Inc. | $2.8B | 28.8% | |||
| 95 | AGIOAgios Pharmaceuticals, Inc. | $1.8B | 33.6% | |||
| 96 | DNTHDianthus Therapeutics, Inc. | $4.5B | 30.1% | |||
| 97 | MAZEMaze Therapeutics, Inc. | $1.7B | 41.3% | |||
| 98 | ELVNEnliven Therapeutics, Inc. | $3.2B | 29.0% | |||
| 99 | PCVXVaxcyte, Inc. | $9.8B | 31.6% | |||
| 100 | ZBIOZenas BioPharma, Inc. | $1.9B | 36.3% | |||
| 101 | SRRKScholar Rock Holding Corporatio | $5.3B | 28.9% | |||
| 102 | INSMInsmed Incorporated | $24.7B | 47.1% | |||
| 103 | GENBGenerate Biomedicines, Inc. | $1.9B | 36.2% | |||
| 104 | RAREUltragenyx Pharmaceutical Inc. | $1.6B | 59.6% | |||
| 105 | BLTEBelite Bio, Inc | $6.2B | 22.6% | |||
| 106 | MNKDMannKind Corporation | $1.1B | 46.2% | |||
| 107 | SRPTSarepta Therapeutics, Inc. | $2.0B | 24.6% | |||
| 108 | RYTMRhythm Pharmaceuticals, Inc. | $6.3B | 24.2% | |||
| 109 | GHRSGH Research PLC | $1.4B | 33.6% | |||
| 110 | IDYAIDEAYA Biosciences, Inc. | $3.1B | 25.1% | |||
| 111 | DNLIDenali Therapeutics Inc. | $3.0B | 30.6% | |||
| 112 | COAGHemab Therapeutics Holdings, In | $1.9B | 25.2% | |||
| 113 | STOKStoke Therapeutics, Inc. | $1.7B | 34.6% | |||
| 114 | ARWRArrowhead Pharmaceuticals, Inc. | $8.4B | 37.3% | |||
| 115 | IMNMImmunome, Inc. | $2.1B | 39.4% | |||
| 116 | NKTRNektar Therapeutics | $1.3B | 64.3% | |||
| 117 | TRVITrevi Therapeutics, Inc. | $1.9B | 32.9% | |||
| 118 | MDGLMadrigal Pharmaceuticals, Inc. | $9.9B | 30.0% | |||
| 119 | IMTXImmatics N.V. | $1.1B | 42.0% | |||
| 120 | MIRMMirum Pharmaceuticals, Inc. | $5.5B | 34.6% | |||
| 121 | IMVTImmunovant, Inc. | $6.0B | 35.8% | |||
| 122 | RCUSArcus Biosciences, Inc. | $2.3B | 42.7% | |||
| 123 | CLDXCelldex Therapeutics, Inc. | $2.4B | 33.3% | |||
| 124 | BNTXBioNTech SE | $22.1B | 28.9% | |||
| 125 | SNDXSyndax Pharmaceuticals, Inc. | $1.2B | 46.7% | |||
| 126 | NUVBNuvation Bio Inc. | $1.7B | 51.2% | |||
| 127 | TSHATaysha Gene Therapies, Inc. | $1.3B | 43.4% | |||
| 128 | SPTXSeaport Therapeutics, Inc. | $1.0B | 30.9% | |||
| 129 | CYTKCytokinetics, Incorporated | $8.8B | 28.7% | |||
| 130 | VERAVera Therapeutics, Inc. | $2.2B | 44.7% | |||
| 131 | AVLNAvalyn Pharma Inc. | $1.1B | 36.2% | |||
| 132 | DYNDyne Therapeutics, Inc. | $3.1B | 38.9% | |||
| 133 | RAPPRapport Therapeutics, Inc. | $1.5B | 52.7% | |||
| 134 | AXSMAxsome Therapeutics, Inc. | $7.6B | 44.5% | |||
| 135 | OCULOcular Therapeutix, Inc. | $1.5B | 57.6% | |||
| 136 | VKTXViking Therapeutics, Inc. | $3.5B | 36.8% | |||
| 137 | AAPGAscentage Pharma Group Internat | $1.4B | 58.1% | |||
| 138 | INBXInhibrx Biosciences, Inc. | $1.1B | 53.8% | |||
| 139 | CELCCelcuity Inc. | $3.4B | 54.2% | |||
| 140 | MLTXMoonLake Immunotherapeutics | $1.0B | 49.4% | |||
| 141 | TYRATyra Biosciences, Inc. | $1.4B | 48.2% | |||
| 142 | ABVXAbivax SA | $7.6B | 41.8% | |||
| 143 | NAMSNewAmsterdam Pharma Company N.V | $2.4B | 52.5% | |||
| 144 | QUREuniQure N.V. | $1.7B | 63.8% | |||
| 145 | XENEXenon Pharmaceuticals Inc. | $3.6B | 48.5% | |||
| 146 | KARDKardigan, Inc. | $1.3B | 47.7% | |||
| 147 | IONSIonis Pharmaceuticals, Inc. | $7.2B | 49.8% | |||
| 148 | KLRAKailera Therapeutics, Inc. | $1.7B | 54.4% | |||
| 149 | MLYSMineralys Therapeutics, Inc. | $1.6B | 61.8% | |||
| 150 | GPCRStructure Therapeutics Inc. | $1.6B | 77.0% | |||
| 151 | KRSAKorsana Biosciences, Inc. | $1.4B | 49.2% | |||
| 152 | ADRXADARx Pharmaceuticals, Inc. | $1.9B | — | |||
| 153 | BRVEBraveheart Bio, Inc. | $1.9B | — | |||
| 154 | CTYCity Therapeutics, Inc. | $1.0B | — | |||
| 155 | LYCALycia Therapeutics, Inc. | $1.4B | — |
In order of their Comp rating. The ratings themselves, and the same day's ranking, are for members. Sign in or start for €6.99 a month.
See every rating for €6.99 a month
Nearby in the ranking
- Utilities - Regulated Water #23
- Information Technology Services #24
- Consulting Services #26
- Drug Manufacturers - General #27